Skip to main content
OBIO
NASDAQ Industrial Applications And Services

Orchestra BioMed Q3 Loss Narrows to $18.8M; Cash Runway Extended to 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.73
Mkt Cap
$344.402M
52W Low
$3.46
52W High
$6.5
52W Position info
66% above low
Off High info
12% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

OBIO sits 66% above its 52-week low of $3.46.

Summary

Orchestra BioMed posted a Q3 net loss of $18.75M (vs $20.83M a year ago) and ended September with $101.9M in cash and securities; management now projects funding through 2028, bolstered by the $80.5M net raised in its November offering.


Key Events · Earnings and Guidance · OBIO

  • Q3 Net Loss Narrows to $18.75M

    Third-quarter net loss was $18.75M versus $20.83M in Q3 2025; nine-month net loss widened to $63.2M from $58.9M.

  • Cash Runway Extended Through 2028

    Company held $101.9M in cash, equivalents and marketable securities at September 30, 2026 ($27.8M cash + $74.1M securities), and projects funding through 2028.

  • R&D Spend Climbs 21% on Trial Ramp

    Nine-month R&D rose to $50.1M from $41.4M, driven by BACKBEAT and Virtue trial costs; Q3 R&D was $17.7M versus $14.0M.

  • Interest Expense Jumps on New Debt

    Net interest expense reached $5.1M for nine months versus $385K a year earlier, reflecting the Ligand royalty liability and Medtronic convertible note.


Analysis · OBIO · Industrial Applications And Services

The bottom line improved modestly, with Q3 net loss of $18.75M versus $20.83M a year earlier, helped by an $8.4M gain on the sale of its Vivasure stake and a $1.2M non-cash gain from remeasuring the Series A preferred derivative. Offsetting that, R&D spending climbed 21% to $50.1M for the nine months as the BACKBEAT and Virtue trials ramp, and net interest expense jumped to $5.1M from $385K as the Ligand royalty and Medtronic note began accruing. Liquidity is the key takeaway: $101.9M in cash and marketable securities at quarter-end, plus the $80.5M net raised in the November 9 offering, gives management a runway it now projects through 2028 — removing near-term financing risk while the pivotal trials read out.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OBIO was trading at $5.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $344.4M. The 52-week trading range was $3.46 to $6.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OBIO - Latest Insights

OBIO
Nov 06, 2026, 5:11 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.68
Real-time Price: $6.01 info
Change: +$0.330 (+6%) info
Market Cap: $361.231M info
OBIO
Nov 05, 2026, 10:43 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $6.01 info
Change: +$1.01 (+20%) info
Market Cap: $361.231M info
OBIO
Nov 05, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $5.56
Real-time Price: $6.01 info
Change: +$0.450 (+8%) info
Market Cap: $361.231M info
OBIO
Nov 05, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.70
Real-time Price: $6.01 info
Change: +$1.31 (+28%) info
Market Cap: $361.231M info
OBIO
Oct 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.08
Real-time Price: $6.01 info
Change: -$0.070 (-1%) info
Market Cap: $361.231M info